Compare PDLB & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | VYGR |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.1M | 216.3M |
| IPO Year | 2021 | 2015 |
| Metric | PDLB | VYGR |
|---|---|---|
| Price | $20.42 | $3.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 63.0K | ★ 414.1K |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | $28.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.91 | $2.94 |
| 52 Week High | $21.10 | $5.55 |
| Indicator | PDLB | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 41.61 |
| Support Level | $19.66 | $2.95 |
| Resistance Level | $20.81 | $3.30 |
| Average True Range (ATR) | 0.40 | 0.15 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 60.20 | 10.99 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.